{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T02:22:39Z","timestamp":1782526959572,"version":"3.54.5"},"reference-count":137,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA1201100"],"award-info":[{"award-number":["2021YFA1201100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Cancer Center"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jncc.2026.01.004","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T21:47:24Z","timestamp":1772228844000},"page":"259-273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety comparisons of PD-1 versus PD-L1 inhibitors in patients with solid cancer: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"6","author":[{"given":"Jun","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoxia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoran","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yezhen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangli","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihui","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jncc.2026.01.004_bib0001","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"issue":"6382","key":"10.1016\/j.jncc.2026.01.004_bib0002","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jncc.2026.01.004_bib0003","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8:561","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.jncc.2026.01.004_bib0004","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2217\/imt-2018-0110","article-title":"Programmed cell death-1\/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action","volume":"11","author":"Zhang","year":"2019","journal-title":"Immunotherapy"},{"issue":"8","key":"10.1016\/j.jncc.2026.01.004_bib0005","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"10358","key":"10.1016\/j.jncc.2026.01.004_bib0006","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","article-title":"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial","volume":"400","author":"Pal","year":"2022","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.jncc.2026.01.004_bib0007","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jncc.2026.01.004_bib0008","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jtho.2022.09.223","article-title":"NEPTUNE: phase 3 study of first-line durvalumab plus tremelimumab in patients with metastatic NSCLC","volume":"18","author":"de Castro","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.jncc.2026.01.004_bib0009","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.jncc.2026.01.004_bib0010","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O'Brien","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10308","key":"10.1016\/j.jncc.2026.01.004_bib0011","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.jncc.2026.01.004_bib0012","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2217\/fon-2021-1647","article-title":"KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer","volume":"18","author":"Rizzo","year":"2022","journal-title":"Future Oncol"},{"issue":"19","key":"10.1016\/j.jncc.2026.01.004_bib0013","doi-asserted-by":"crossref","first-page":"11363","DOI":"10.3390\/ijms231911363","article-title":"Challenges and future trends of hepatocellular carcinoma immunotherapy","volume":"23","author":"Rizzo","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.jncc.2026.01.004_bib0014","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 Inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"issue":"19","key":"10.1016\/j.jncc.2026.01.004_bib0015","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"10183","key":"10.1016\/j.jncc.2026.01.004_bib0016","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jncc.2026.01.004_bib0017","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1\u2013selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.jncc.2026.01.004_bib0018","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.2018.36.15_suppl.3065","article-title":"A meta-analysis to indirectly compare the safety and efficacy of PD-1 and PD-L1 antibodies across solid tumors using a Bayesian hierarchical model","volume":"36","author":"Koneru","year":"2018","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.jncc.2026.01.004_bib0019","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.3390\/jcm10163612","article-title":"Comparative impact of PD-1 and PD-L1 inhibitors on advanced esophageal or gastric\/gastroesophageal junction cancer treatment: a systematic review and meta-analysis","volume":"10","author":"Oh","year":"2021","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.jncc.2026.01.004_bib0020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cncr.31043","article-title":"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature","volume":"124","author":"Pillai","year":"2018","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.jncc.2026.01.004_bib0021","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.7150\/jca.22361","article-title":"A network meta-analysis comparing the efficacy and safety of anti-PD-1 with anti-PD-L1 in non-small cell lung cancer","volume":"9","author":"You","year":"2018","journal-title":"J Cancer"},{"issue":"1","key":"10.1016\/j.jncc.2026.01.004_bib0022","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s40425-018-0427-6","article-title":"Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?","volume":"6","author":"Zhang","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jncc.2026.01.004_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.705096","article-title":"Anti-PD-1 and anti-PD-L1 in head and neck cancer: a network meta-analysis","volume":"12","author":"Botticelli","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jncc.2026.01.004_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102242","article-title":"Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"99","author":"Mori","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jncc.2026.01.004_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106852","article-title":"The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: a systematic review and meta-analysis","volume":"87","author":"Yi","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"7387","key":"10.1016\/j.jncc.2026.01.004_bib0026","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses","volume":"326","author":"Song","year":"2003","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jncc.2026.01.004_bib0027","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","article-title":"Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis","volume":"6","author":"Duan","year":"2020","journal-title":"JAMA Oncol"},{"issue":"10111","key":"10.1016\/j.jncc.2026.01.004_bib0028","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jncc.2026.01.004_bib0029","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300","volume":"29","author":"Bang","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jncc.2026.01.004_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v106.i02","article-title":"netmeta: an R package for network meta-analysis using frequentist methods","volume":"106","author":"Balduzzi","year":"2023","journal-title":"J Stat Softw"},{"issue":"4","key":"10.1016\/j.jncc.2026.01.004_bib0031","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res Synth Methods"},{"issue":"1","key":"10.1016\/j.jncc.2026.01.004_bib0032","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"van Valkenhoef","year":"2016","journal-title":"Res Synth Methods"},{"issue":"9985","key":"10.1016\/j.jncc.2026.01.004_bib0033","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/S0140-6736(15)60263-X","article-title":"Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials","volume":"385","author":"Palmerini","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jncc.2026.01.004_bib0034","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.jncc.2026.01.004_bib0035","article-title":"Efficacy and safety of anti-PD1\/PDL1 in advanced biliary tract cancer: a systematic review and meta-analysis","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jncc.2026.01.004_bib0036","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2026.01.004_bib0037","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"issue":"17","key":"10.1016\/j.jncc.2026.01.004_bib0038","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jncc.2026.01.004_bib0039","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.jncc.2026.01.004_bib0040","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4081\/oncol.2020.490","article-title":"Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm","volume":"14","author":"Banna","year":"2020","journal-title":"Oncol Rev"},{"issue":"7","key":"10.1016\/j.jncc.2026.01.004_bib0041","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00262-020-02536-5","article-title":"Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort","volume":"69","author":"Naqash","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.jncc.2026.01.004_bib0042","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.jncc.2026.01.004_bib0043","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jtho.2018.04.025","article-title":"Italian nivolumab expanded access program in nonsquamous non-small cell lung cancer patients: results in never-smokers and EGFR-mutant patients","volume":"13","author":"Garassino","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.jncc.2026.01.004_bib0044","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.jncc.2026.01.004_bib0045","first-page":"246","article-title":"Meta-analysis of clinical trials in the 2020s and beyond: a paradigm shift needed","volume":"9","author":"Shuster","year":"2023","journal-title":"J Clin Transl Res"},{"issue":"9, Supplement","key":"10.1016\/j.jncc.2026.01.004_bib0046","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.jtho.2022.07.072","article-title":"OA15.03 Avelumab vs chemotherapy for first-line treatment of advanced PD-L1+ NSCLC: primary analysis from JAVELIN lung 100","volume":"17","author":"Reck","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jncc.2026.01.004_bib0047","article-title":"59MO Final analysis of AK105-302: a randomized, double-blind, placebo-controlled, phase III trial of penpulimab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC","volume":"16","author":"Han","year":"2022","journal-title":"Miscellaneous"},{"issue":"15_suppl","key":"10.1016\/j.jncc.2026.01.004_bib0048","doi-asserted-by":"crossref","first-page":"9000","DOI":"10.1200\/JCO.2020.38.15_suppl.9000","article-title":"Randomized phase II clinical trial of cisplatin\/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161","volume":"38","author":"Leal","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jncc.2026.01.004_bib0049","doi-asserted-by":"crossref","first-page":"S1401","DOI":"10.1016\/j.annonc.2022.08.032","article-title":"LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase III trial","volume":"33","author":"Qin","year":"2022","journal-title":"Ann Oncol"},{"issue":"10459","key":"10.1016\/j.jncc.2026.01.004_bib0050","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"issue":"10476","key":"10.1016\/j.jncc.2026.01.004_bib0051","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andre","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jncc.2026.01.004_bib0052","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jtho.2024.09.1381","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic NSCLC: five-year overall survival outcomes from the phase 3 POSEIDON trial","volume":"20","author":"Peters","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.jncc.2026.01.004_bib0053","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.annonc.2021.06.004","article-title":"Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer","volume":"32","author":"Sugawara","year":"2021","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.jncc.2026.01.004_bib0054","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.jncc.2026.01.004_bib0055","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227","volume":"41","author":"Brahmer","year":"2023","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.jncc.2026.01.004_bib0056","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jncc.2026.01.004_bib0057","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score >\/= 1% in the KEYNOTE-042 study","volume":"41","author":"de Castro","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jncc.2026.01.004_bib0058","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","article-title":"Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC","volume":"16","author":"Jassem","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"21","key":"10.1016\/j.jncc.2026.01.004_bib0059","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 Tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10274","key":"10.1016\/j.jncc.2026.01.004_bib0060","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jncc.2026.01.004_bib0061","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/JCO.22.00727","article-title":"Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01)","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jncc.2026.01.004_bib0062","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jtho.2023.03.008","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in advanced NSCLC: 2-year follow-up from the phase 3 EMPOWER-lung 3 part 2 trial","volume":"18","author":"Makharadze","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.jncc.2026.01.004_bib0063","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","article-title":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jncc.2026.01.004_bib0064","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jncc.2026.01.004_bib0065","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jncc.2026.01.004_bib0066","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.jncc.2026.01.004_bib0067","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jncc.2026.01.004_bib0068","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/cac2.12385","article-title":"Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)","volume":"42","author":"Shi","year":"2022","journal-title":"Cancer Commun"},{"issue":"5","key":"10.1016\/j.jncc.2026.01.004_bib0069","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jtho.2019.01.006","article-title":"Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial","volume":"14","author":"Wu","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2026.01.004_bib0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jtho.2022.09.217","article-title":"Tislelizumab versus docetaxel in patients with previously treated advanced NSCLC (RATIONALE-303): a phase 3, open-label, randomized controlled trial","volume":"18","author":"Zhou","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2026.01.004_bib0071","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jtho.2020.09.022","article-title":"Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials","volume":"16","author":"Mazieres","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.jncc.2026.01.004_bib0072","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.jncc.2026.01.004_bib0073","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ijc.34532","article-title":"KEYNOTE-033: randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC","volume":"153","author":"Ren","year":"2023","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.jncc.2026.01.004_bib0074","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jtho.2021.03.009","article-title":"Avelumab versus docetaxel in patients with platinum-treated advanced NSCLC: 2-year follow-up from the JAVELIN lung 200 phase 3 trial","volume":"16","author":"Park","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.jncc.2026.01.004_bib0075","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial","volume":"17","author":"Ren","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.jncc.2026.01.004_bib0076","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jncc.2026.01.004_bib0077","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.jncc.2026.01.004_bib0078","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","article-title":"Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12)","volume":"16","author":"Zhou","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.jncc.2026.01.004_bib0079","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial","volume":"15","author":"Jotte","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.jncc.2026.01.004_bib0080","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jtho.2022.12.017","article-title":"Camrelizumab plus carboplatin and pemetrexed as first-line treatment for advanced nonsquamous NSCLC: extended follow-up of CameL phase 3 trial","volume":"18","author":"Zhou","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2026.01.004_bib0081","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jtho.2020.09.015","article-title":"Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC","volume":"16","author":"Awad","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.jncc.2026.01.004_bib0082","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jncc.2026.01.004_bib0083","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","article-title":"Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial","volume":"16","author":"Lu","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.jncc.2026.01.004_bib0084","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jncc.2026.01.004_bib0085","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 Trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.jncc.2026.01.004_bib0086","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","article-title":"Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11)","volume":"15","author":"Yang","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.jncc.2026.01.004_bib0087","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","article-title":"Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331(\u2606)","volume":"32","author":"Spigel","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.jncc.2026.01.004_bib0088","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jtho.2019.01.008","article-title":"A randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: results from the IFCT-1603 trial","volume":"14","author":"Pujol","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.jncc.2026.01.004_bib0089","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jncc.2026.01.004_bib0090","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.jncc.2026.01.004_bib0091","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jncc.2026.01.004_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.jncc.2026.01.004_bib0093","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jncc.2026.01.004_bib0094","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jncc.2026.01.004_bib0095","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jncc.2026.01.004_bib0096","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.jncc.2026.01.004_bib0097","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jncc.2026.01.004_bib0098","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100385","article-title":"Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study","volume":"7","author":"Park","year":"2022","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.jncc.2026.01.004_bib0099","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jncc.2026.01.004_bib0100","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jncc.2026.01.004_bib0101","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"issue":"10189","key":"10.1016\/j.jncc.2026.01.004_bib0102","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jncc.2026.01.004_bib0103","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jncc.2026.01.004_bib0104","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.jncc.2026.01.004_bib0105","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10236","key":"10.1016\/j.jncc.2026.01.004_bib0106","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jncc.2026.01.004_bib0107","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.jncc.2026.01.004_bib0108","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.19.03091","article-title":"Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer","volume":"38","author":"Galsky","year":"2020","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.jncc.2026.01.004_bib0109","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jncc.2026.01.004_bib0110","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2026.01.004_bib0111","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eururo.2021.03.024","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma: a long-term overall survival and safety update from the phase 3 IMvigor211 clinical trial","volume":"80","author":"van der Heijden","year":"2021","journal-title":"Eur Urol"},{"issue":"22","key":"10.1016\/j.jncc.2026.01.004_bib0112","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jncc.2026.01.004_bib0113","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jncc.2026.01.004_bib0114","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.annonc.2022.12.008","article-title":"Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study","volume":"34","author":"Psyrri","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.jncc.2026.01.004_bib0115","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.jncc.2026.01.004_bib0116","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jncc.2026.01.004_bib0117","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.annonc.2020.04.001","article-title":"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study","volume":"31","author":"Ferris","year":"2020","journal-title":"Ann Oncol"},{"issue":"10167","key":"10.1016\/j.jncc.2026.01.004_bib0118","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jncc.2026.01.004_bib0119","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jncc.2026.01.004_bib0120","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jncc.2026.01.004_bib0121","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001806","article-title":"KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma","volume":"8","author":"Ferrucci","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"13","key":"10.1016\/j.jncc.2026.01.004_bib0122","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.21.01601","article-title":"Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600-mutant unresectable or metastatic melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2026.01.004_bib0123","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1470-2045(22)00687-8","article-title":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF(V600) mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study","volume":"24","author":"Ascierto","year":"2023","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jncc.2026.01.004_bib0124","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"issue":"33","key":"10.1016\/j.jncc.2026.01.004_bib0125","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1200\/JCO.21.00334","article-title":"Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA)","volume":"39","author":"Hamanishi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.jncc.2026.01.004_bib0126","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1200\/JCO.2022.40.4_suppl.378","article-title":"A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1","volume":"40","author":"Oh","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10391","key":"10.1016\/j.jncc.2026.01.004_bib0127","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jncc.2026.01.004_bib0128","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"issue":"8_Supplement","key":"10.1016\/j.jncc.2026.01.004_bib0129","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT005","article-title":"Abstract CT005: AEGEAN: a phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC","volume":"83","author":"Heymach","year":"2023","journal-title":"Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.jncc.2026.01.004_bib0130","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1200\/JCO.2023.41.16_suppl.8501","article-title":"Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II\/III non-small cell lung cancer (NSCLC): interim event-free survival (EFS) analysis of the phase III NEOTORCH study","volume":"41","author":"Lu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jncc.2026.01.004_bib0131","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jncc.2026.01.004_bib0132","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jncc.2026.01.004_bib0133","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.jncc.2026.01.004_bib0134","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","article-title":"Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.jncc.2026.01.004_bib0135","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jncc.2026.01.004_bib0136","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1470-2045(23)00016-5","article-title":"Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"24","author":"Pignata","year":"2023","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.jncc.2026.01.004_bib0137","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Journal of the National Cancer Center"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667005426000050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667005426000050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:17:59Z","timestamp":1781212679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667005426000050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":137,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2667005426000050"],"URL":"https:\/\/doi.org\/10.1016\/j.jncc.2026.01.004","relation":{},"ISSN":["2667-0054"],"issn-type":[{"value":"2667-0054","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety comparisons of PD-1 versus PD-L1 inhibitors in patients with solid cancer: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Cancer Center","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jncc.2026.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Chinese National Cancer Center. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}